sNFL applicability as additional monitoring tool in Natalizumab Extended Interval Dosing regimen for RRMS patients

被引：0
|
作者：
Valentino, P. [1 ,2 ]
Malucchi, S. [3 ]
Martire, S. [4 ]
Bava, C. I. [1 ]
Capobianco, M. A. [2 ,5 ]
Bertolotto, A. [1 ,6 ]
机构：
[1] Neurosci Inst Cavalieri Ottolenghi NICO, Orbassano, Italy
[2] Univ Hosp San Luigi Gonzaga, CRESM Biobank, Orbassano, Italy
[3] Univ Hosp San Luigi Gonzaga, Neurol, Orbassano, Italy
[4] Univ Turin, Neurosci, Turin, Italy
[5] S Croce Carle Hosp, Neurol, Cuneo, Italy
[6] Koelliker Hosp, Turin, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1244
引用
收藏
页码：1006 / 1007
页数：2
相关论文
共 50 条
  • [1] sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients
    Valentino, Paola
    Malucchi, Simona
    Martire, Serena
    Bava, Cecilia Irene
    Capobianco, Marco Alfonso
    Bertolotto, Antonio
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [2] Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
    Mancinelli, Chiara Rosa
    Scarpazza, Cristina
    Cordioli, Cinzia
    De Rossi, Nicola
    Rasia, Sarah
    Turrini, Maria Vittoria
    Capra, Ruggero
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 790 - 794
  • [3] MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
    De Mercanti, Stefania Federica
    Signori, Alessio
    Cordioli, Cinzia
    Signoriello, Elisabetta
    Lus, Giacomo
    Bonavita, Simona
    Abbadessa, Gianmarco
    Lavorgna, Luigi
    Maniscalco, Giorgia Teresa
    Curti, Erica
    Lorefice, Lorena
    Cocco, Eleonora
    Nociti, Viviana
    Mirabella, Massimiliano
    Baroncini, Damiano
    Mataluni, Giorgia
    Landi, Doriana
    Petruzzo, Martina
    Lanzillo, Roberta
    Gandoglia, Ilaria
    Laroni, Alice
    Frangiamore, Rita
    Sartori, Arianna
    Cavalla, Paola
    Costantini, Gianfranco
    Capra, Ruggero
    Sormani, Maria Pia
    Clerico, Marinella
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
  • [4] Effectiveness of Natalizumab in Extended Dosing Interval
    Hervas, Jose Vicente
    Punet-Ortiz, Joan
    Teniente-Serra, Aina
    Mansilla, M. Jos
    Quirant-Sanchez, Bibiana
    Navarro, Juan
    Presas, Silvia
    Martinez-Caceres, Eva
    Ramo, Cristina
    NEUROLOGY, 2016, 86
  • [5] Effectiveness of natalizumab in extended dosing interval
    Ramo-Tello, C.
    Grau-Lopez, L.
    Vilaro, L.
    Segui, C.
    Delicado, S.
    Bonafont, X.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 214
  • [6] Radiographic disease activity in patients on natalizumab extended interval dosing
    Ryerson, L. Zhovtis
    Hoyt, T.
    Metzger, R.
    Christensen, A.
    Zuniga-Estrada, G.
    Jacob, A.
    Gragui, D.
    Bacon, T.
    Li, X.
    Goldberg, J.
    Kister, I.
    Foley, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 909 - 909
  • [7] Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients
    Petrzalka, M.
    Meluzinova, E.
    Mojzisova, H.
    Libertinova, J.
    Rockova, P.
    Nema, E.
    Elisak, M.
    Marusic, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (01) : 79 - 83
  • [8] Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID)
    Foley, John
    Xiong, Kuangan
    Hoyt, Tammy
    Singh, Carol
    Riddle, Evan
    de Moor, Carl
    Campbell, Nolan
    Plavina, Tatiana
    NEUROLOGY, 2020, 94 (15)
  • [9] Extended-interval dosing of natalizumab in NOVA
    Stuve, Olaf
    Tugemann, Bastian
    LANCET NEUROLOGY, 2023, 22 (03): : 199 - 200
  • [10] Efficacy and safety of natalizumab extended interval dosing
    Zeineddine, M.
    Ayyoubi, N.
    Tamim, H.
    Nicolas, J.
    Khoury, S.
    Yamout, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 871 - 871
12345